Oncology News | pharmaphorum

News

FDA approves GSK's Blenrep for advanced multiple myeloma

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease.

News

Incyte/Morphosys take on CAR-Ts with $198,000 per year antib...

Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumberso

News

Regeneron pairs with BioNTech on melanoma immunotherapy

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other ch

News

Roche's NTRK tumour-agnostic therapy Rozlytrek approved in E...

Roche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK mutation, meaning Bayer’s class rival faces competition in Europe for

News

Roche’s Tecentriq claims melanoma OK, but don’t expect a sal...

Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and M

News

BMS 'bet' with Celgene shareholders in balance after CAR-T r...

Bristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a three drug “bet” with former Celgene shareholders dependent on a fast r

FDA approves GSK's Blenrep for advanced multiple myeloma

Incyte/Morphosys take on CAR-Ts with $198,000 per year antib...

Regeneron pairs with BioNTech on melanoma immunotherapy

Roche's NTRK tumour-agnostic therapy Rozlytrek approved in E...

Roche’s Tecentriq claims melanoma OK, but don’t expect a sal...

BMS 'bet' with Celgene shareholders in balance after CAR-T r...

Simple blood test could aid in global TB fight

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks